Key Takeaways The Food and Drug Administration put clinical holds on Novavax's COVID-19 and flu combination vaccine and its ...

The regulator placed a clinical hold on its Covid-19-influenza combination vaccine after one person reported nerve damage.

The U.S. Food and Drug Administration has put on hold a trial of Novavax's COVID-influenza and its standalone flu vaccines ...

How bad is this news for Novavax? Let's find out. Image source: Getty Images.

Novavax Inc. (NASDAQ:NVAX) stock is trading lower on Wednesday. The FDA has placed a clinical hold on Novavax’s ...

Novavax’s plans for growth outside of its COVID program have been thrown into chaos after the FDA put the biooharma's flu ...

The clinical hold affects Novavax’s COVID-flu combo and standalone flu vaccines, which were on the cusp of Phase III testing.

The hold, which was made in response to a serious adverse event report, could impact the company’s plans to start a Phase 3 ...

A report of a case of motor neuropathy in a patient who received the vaccine last year has led the FDA to halt its ...

Novavax shares tumbled after the Food and Drug Administration put a clinical hold on its testing applications for a combined ...

Shares of US protein-based vaccine maker Novavax closed down 19.4% at $10.15 yesterday having dropped as much as 24%, on the ...

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Novavax, Inc. (“Novavax” or ...